Mepolizumab—a novel option for the treatment of hypereosinophilic syndrome in childhood

Publisher: John Wiley & Sons Inc

E-ISSN: 1399-3038|29|1|28-33

ISSN: 0905-6157

Source: PEDIATRIC ALLERGY AND IMMUNOLOGY, Vol.29, Iss.1, 2018-02, pp. : 28-33

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract